Brain Tumor Compositions Combining Seviteronel and Radiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing metalloenzyme inhibitors face challenges in achieving a balance between potency and selectivity, leading to potential clinical toxicity due to indiscriminate binding to off-target enzymes, as seen in treatments for prostate cancer and matrix metalloproteinase inhibitors.
Innovation Solution
The use of compounds of Formula (I) or seviteronel, administered alone or in combination with radiation therapy and optionally dexamethasone, to target brain tumors by modulating metalloenzyme activity, thereby enhancing treatment efficacy while minimizing off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a very tightly binding metal-binding group is utilized, then potency is improved, but selectivity for the target enzyme versus related metalloenzymes deteriorates
Solution Approach 1:
The patent modifies the metal-binding group parameters by introducing a specific 1-imidazole group at a defined position relative to the CYP17 target enzyme, optimizing the binding affinity to achieve high potency while maintaining selectivity through precise structural parameter control
Solution Approach 2:
The invention applies local quality by placing the metal-binding group at a specific location (position 1 relative to the CYP17 enzyme) rather than using a generic binding group, creating localized high-affinity binding at the target site while avoiding off-target binding
2Ease of manufacture
If a commonly used metal-binding group is utilized, then ease of manufacture is improved, but clinical toxicity worsens due to off-target inhibition
Solution Approach 1:
The patent extracts the problematic indiscriminate binding characteristic from the metal-binding group by introducing a specific 1-imidazole group positioned to bind only to CYP17, separating the desired target binding from the harmful off-target binding that causes clinical toxicity
Solution Approach 2:
The specific 1-imidazole group acts as an intermediary element that mediates selective binding to CYP17 while preventing binding to other metalloenzymes, thus reducing clinical toxicity while maintaining manufacturability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described approach effectively treats brain tumors by selectively inhibiting metalloenzymes, reducing tumor growth, and mitigating side effects associated with non-specific binding, thus providing a balanced therapeutic response.
Implementation Method 1
agents which bind to and inactivate the active site metal ion dramatically decrease the activity of the enzyme
Implementation Method 2
the administration of radiation therapy and an effective amount of: 1) a compound of Formula (I)
Data Source
AI summary
The instant invention describes pharmaceutical compositions and dosing regimens comprising radiation therapy and seviteronel with or without dexamethasone, and methods of treating diseases, disorders or symptoms thereof.